[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hyšpler et al., 2018 - Google Patents

Indoxyl sulfate elimination in renal replacement therapy: influence of citrate‐versus acetate‐buffering component during bicarbonate dialysis

Hyšpler et al., 2018

View PDF @Full View
Document ID
13669024566574790672
Author
Hyšpler R
Tichá A
Šafránek R
Moučka P
Nývltová Z
Štochlová K
Dusilová-Sulková S
Zadák Z
Publication year
Publication venue
Disease Markers

External Links

Snippet

Indoxyl sulfate has been identified as a major factor in the dysregulation of several genes. It is classified as a poorly dialyzable uremic toxin and thus a leading cause in the poor survival rate of dialysis patients. A monocentric, prospective, open cohort study was performed in 43 …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents

Similar Documents

Publication Publication Date Title
Slack et al. Ammonia clearance with haemofiltration in adults with liver disease
Vanholder et al. What is new in uremic toxicity?
Hyšpler et al. Indoxyl sulfate elimination in renal replacement therapy: influence of citrate‐versus acetate‐buffering component during bicarbonate dialysis
Meert et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications
Kandouz et al. Reduced protein bound uraemic toxins in vegetarian kidney failure patients treated by haemodiafiltration
Tao et al. Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study
Gritters et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis
Evans et al. Pharmacokinetics of L‐carnitine in patients with end‐stage renal disease undergoing long‐term hemodialysis
Lin et al. p‐Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease
Brettschneider et al. Removal of protein‐bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique
Yamamoto et al. Changes in circulating biomarkers during a single hemodialysis session
Nakae et al. Selective plasma exchange with dialysis in patients with acute liver failure
Sjöberg et al. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation
Camacho et al. Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate
Lim et al. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial
Schmuck et al. Single Pass Albumin Dialysis—A Dose‐Finding Study to Define Optimal Albumin Concentration and Dialysate Flow
Vanholder et al. New methods and technologies for measuring uremic toxins and quantifying dialysis adequacy
Huang et al. High correlation between clearance of renal protein‐bound uremic toxins (indoxyl sulfate and p‐cresyl sulfate) and renal water‐soluble toxins in peritoneal dialysis patients
Hadad‐Arrascue et al. Expanded hemodialysis as effective alternative to on‐line hemodiafiltration: A randomized mid‐term clinical trial
Terawaki et al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients
Carello et al. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats
Shi et al. Improved dialytic removal of protein-bound uremic toxins by intravenous lipid emulsion in chronic kidney disease rats
Campostrini et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI‐TOF MS
Bergé-Lefranc et al. Binding of p-cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry
Krieter et al. Clinical performance comparison of two medium cut‐off dialyzers